About
Technology
Issues
FAQ
Links
Official Page
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.